ReviewFrontiers in psychiatry2020
Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.
Review in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Comparison of resting-state brain activity between insomnia and generalized anxiety disorder: A coordinate-based meta-analysis.Brain imaging and behavior · 2025Pooled it
- Pharmacological modulation of conditioned fear in the fear-potentiated startle test: a systematic review and meta-analysis of animal studies.Psychopharmacology · 2023Pooled it
- Neuroimaging Insights: Kava's (Nutrients · 2023Trial
- Comparative Effects of Behavioral Analysis Therapy of Feelings and Brief Focal Psychotherapy: Protocol for a Randomized Controlled Assessor-Blinded Clinical Trial.Medical sciences (Basel, Switzerland) · 2026Article
- Integrative metabolomics and machine learning identify biomarkers of adolescent social anxiety disorder.World journal of pediatrics : WJP · 2026Article
- Developmental trajectories of glutamate and the variable clinical course of ADHD in youth.Translational psychiatry · 2026Article
- Age-Related Differences and Effects of Internalizing Symptoms on Aperiodic Neural Activity in Adolescents.Psychophysiology · 2026Article
- Metabotropic glutamate receptors: Allosteric structural modulation and new treatments for anxiety disorders.Neurosciences (Riyadh, Saudi Arabia) · 2025Review
- Generalized Anxiety Disorder and Obesity: Overlapping Neuroendocrine, Metabolic, and Behavioral Pathways.Nutrients · 2025Review
- A Proton Magnetic Resonance Spectroscopy (International journal of molecular sciences · 2025Article
- The Quantum Paradox in Pharmaceutical Science: Understanding Without Comprehending-A Centennial Reflection.International journal of molecular sciences · 2025Review
- Astrocytes in Rodent Anxiety-Related Behavior: Role of Calcium and Beyond.International journal of molecular sciences · 2025Review
- Human oral microbiome and its influence on mental health and brain disorders.AIMS microbiology · 2025Review
- Future Directions in Anxiolytic Therapy: A Comprehensive Review of Novel Targets and Strategies.Current neurovascular research · 2025Review
- Anterior insular cortex glutamate-glutamine (Glx) levels predict general psychopathology via heightened error sensitivity.Frontiers in neuroscience · 2025Article
- A case report of pregabalin misuse leading to drug dependence.Frontiers in psychiatry · 2025Article
- Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms.The international journal of neuropsychopharmacology · 2024Review
- Intravenous patient-controlled analgesia with esketamine improves early depressive symptoms in patients with postherpetic neuralgia: a single-center retrospective cohort study.BMC psychiatry · 2024Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively. Although clearly effective, these medications fail to improve anxiety symptoms in a significant proportion of patients. New insights into the glutamate system have directed attention toward drugs that modulate glutamate as potential alternative treatments for anxiety disorders. Here we summarize the current understanding of the potential role of glutamate neurotransmission in anxiety disorders and highlight specific glutamate receptors that are potential targets for novel anxiety disorder treatments. We also review clinical trials of medications targeting the glutamate system in DSM-5 anxiety disorders. Understanding the role of the glutamate system in the pathophysiology of anxiety disorder may aid in developing novel pharmacological agents that are effective in treating anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.